The Fifth Circuit Just Reinstated the In-Person Requirement for Mifepristone — and Alito Put a One-Week Pin in It
The Fifth Circuit Just Reinstated the In-Person Requirement for Mifepristone — and Alito Put a One-Week Pin in It
What actually happened
On May 1, 2026, a unanimous three-judge panel of the U.S. Court of Appeals for the Fifth Circuit — Judges Stuart Kyle Duncan, Cory Wilson, and Edith Brown Clement, all Republican appointees — issued a ruling that blocks mail and telehealth access to mifepristone nationwide. The ruling grants a stay that reinstates the in-person dispensing requirement for the drug, which the FDA permanently lifted in 2023 after determining the restriction was medically unnecessary.
The case is Louisiana v. FDA. The state of Louisiana sued, claiming FDA's elimination of the in-person requirement violated the Administrative Procedure Act. Louisiana argued the agency relied on insufficient data and that mail-order mifepristone undermines the state's abortion ban and costs its Medicaid program money for treating complications . The Fifth Circuit agreed Louisiana is likely to succeed on the merits, finding FDA's "progressive relaxation of mifepristone's guardrails likely lacked a basis in data and scientific literature".
On May 2, manufacturers Danco and GenBioPro filed an emergency application with the U.S. Supreme Court to block the Fifth Circuit's ruling . On May 4, Justice Samuel Alito issued an administrative stay — a temporary pause — that keeps current mail and telehealth access in place until 5 p.m. EDT on May 11, 2026, while the Court considers the full stay request. The Court has ordered Louisiana to file its response by May 7.
The system at work
This is the same legal infrastructure that dismantled Roe — the Fifth Circuit, the emergency docket, and the conservative movement's decades-long project of using the judiciary to rewrite federal drug policy state by state.
The mechanism is standing laundering. In 2024, the Supreme Court ruled in FDA v. Alliance for Hippocratic Medicine that anti-abortion physicians lacked standing to challenge mifepristone access . So the movement switched plaintiffs. Instead of doctors, they used a state government — Louisiana — which claims sovereign injury from a federal drug regulation . The Fifth Circuit accepted that a state has standing to challenge FDA policy because mail-order pills "cancel" Louisiana's abortion ban. That is new law the Fifth Circuit just made. One state's policy preference is now grounds for a nationwide injunction.
The Fifth Circuit's reasoning is transparent: "Every abortion facilitated by FDA's action cancels Louisiana's ban on medical abortions and undermines its policy that 'every unborn child is human being from the moment of conception'" . The court is not applying Chevron deference. It is replacing FDA's scientific judgment with a state's personhood statute.
The administrative stay is not relief. It is a one-week pause on a ruling that should not exist. Alito's order keeps the status quo for seven days. Then the full Court decides whether to make the Fifth Circuit's ban permanent while litigation proceeds.
The real-world harm
Mifepristone is used in nearly two-thirds of U.S. abortions and for early miscarriage management. As of June 2025, approximately 28 percent of all U.S. abortions — about 247,000 in 2024 alone — were performed via telehealth using mifepristone. That is one in four people who had an abortion last year.
If the Fifth Circuit's ruling stands, those people will be required to pick up the medication in person — even if they have already completed a telehealth consultation with a clinician. In states where abortion is legal, that means travel. In rural areas, that can mean hundreds of miles. In states with bans, it means crossing state lines.
The in-person requirement is not medicine. The American Medical Association, the American College of Obstetricians and Gynecologists, and more than a hundred peer-reviewed studies have confirmed that mifepristone prescribed via telehealth has a major adverse event rate below 1 percent. The restriction serves one function: to erect a travel barrier that will price people out of care.
For survivors of domestic violence — who already face surveillance, financial control, and limited mobility — an in-person pickup requirement can be the difference between accessing abortion and being forced to continue a pregnancy with an abuser . For low-income people, a single missed day of work to travel to a clinic can be the difference. For minors, a two-hour drive can require parental disclosure that is unsafe or impossible.
Planned Parenthood of Northern New England announced it will switch to a misoprostol-only protocol for its telehealth program in response to the ruling — a safe alternative, but one that causes more nausea, vomiting, cramping, and prolonged bleeding than the standard two-drug regimen . Patients will now be routed to a physically harder experience because a court decided FDA's data was insufficient.
What happens next
The Supreme Court will decide by May 11 whether to leave the Fifth Circuit's ruling in place. If the Court does not intervene, telehealth mifepristone ends nationwide — not just in Louisiana, not just in ban states, everywhere. That includes California, New York, Oregon, and Washington, where the ACLU and 22 state attorneys general have filed briefs opposing the restriction.
The Trump administration's FDA is currently conducting a separate safety review of mifepristone, announced in May 2025 after pressure from Project 2025-aligned groups. That review has been delayed and is expected to produce further restrictions regardless of what the courts do.
A state that has banned abortion successfully argued in federal court that it is harmed by people in other states accessing legal medication — and a federal appeals court agreed, then used that harm as justification to impose that state's ban on the rest of the country.
She doesn't chase trends. She channels truth.
